Double binding molecules of BCMA and CD3； nucleic acid sequences for coding； vectors； clula； pharmaceutical ingredients including monomolecules； uses for treating diseases related to plasticizing cell degeneration, Type B cell disorders associated with BCMA manifestations and autoimmune diseases
The present invention relates to a binding molecule comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope clusters of BCMA, and the second binding domain is capable of binding to the T cell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule.<；p>；LA INVENCIÓ；N PROPORCIONA UNA MOLÉ；CULA DE UNIÓ；N BIESPECÍ；FICA PARA BCMA Y CD3； SECUENCIA DE Á；CIDO NUCLEICO QUE LA CODIFICA； VECTOR ； CÉ；LULA； COMPOSICIÓ；N FARMACÉ；UTICA QUE COMPRENDE A LA MOLÉ；CULA DE UNIÓ；N； USO PARA TRATAR ENFERMEDADES RELACIONADAS A TRANSTORNOS DE CÉ；LULAS PLASMÁ；TICAS, TRASTORNOS DE CÉ；LULAS B CORRELACIONADOS CON LA EXPRESIÓ；N DE BCMA Y ENFERMEDADES AUTOINMUNES.<；/p>；
